APC Science combines deep technical and operational expertise, inventive problem-solving, and business judgment to find the highest-value path for a drug program, with a clear-eyed read on what is actually feasible, what isn't, and the way around it. Across modalities and stages, hands-on with peptide, antibody, and conjugate chemistry.
A molecule or modality is technically demanding
We assess what is truly feasible, find the route that works, and the inventive way around what doesn't.
A program needs its plan to the next milestone or raise
We map the highest-value path: what matters, in what order, at what cost, and the trade-offs worth making.
A CDMO, CRO, or technical partner has to deliver
We find the right partner and the right approach, and keep the work honest and on track.
An investor or acquirer needs a real read on an asset
We judge feasibility, where value and risk actually sit, and what it will take to realize it.
A platform has more directions than it can fund
We identify the path with the best feasibility, fundability, and strategic value.
Most advisors work the strategy or the science. APC Science does both, so our plans are grounded in what is actually buildable at the molecule level, and our technical work always points at a development and commercial endgame.
Development planning, modality selection, target product profiles, CMC and operational strategy, vendor and CDMO sourcing, and program execution, across modalities and at any stage from discovery to clinic.
Hands-on design and development of peptides, peptide-based antigens and antibody therapeutics, and the harder problems: conjugates, ligands, scaffolds, and non-standard chemistries, through synthesis, conjugation, formulation, and scale-up.
Figures reflect work across Advanced Peptides, SmartLabs, and ventures founded and led by APC Science's founder.
Amrit Chaudhuri founded Advanced Peptides after watching difficult peptide chemistry come back late or unsolved from contract labs. The firm completed more than 3,000 molecular projects for 120+ academic and pharmaceutical organizations. He went on to co-found and lead SmartLabs, scaling research infrastructure across Boston and South San Francisco and raising more than $400M across ventures.
Read the founder's backgroundGuidance shaped by actually building and running research platforms, GMP and GLP programs, and IND-enabling work, not just advising on them.
We connect molecular feasibility to development timelines, capital strategy, and commercial reality, so decisions hold up across every layer.
Out-of-the-box problem-solving grounded in real chemistry and operations: when the obvious route stalls, we find the feasible one: the trade-off, the workaround, or the rethink that moves the program.
A difficult molecule, a development plan, a CDMO decision, a diligence question, or a direction you want pressure-tested. We'll give you a candid read on the best way forward.
Talk through your program